---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-033173"
form_type: "8-K"
ticker: "PPCB"
cik: "0001517681"
company_name: "Propanc Biopharma, Inc."
filed_at: "2026-07-14T20:01:28+00:00"
generated_at: "2026-07-14T20:03:02.289436+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Propanc Biopharma appoints Carlo Campiciano to Board, replacing retiring director Annie Van Broekhoven

## Summary
- Annie Van Broekhoven retired from Board effective July 8, 2026.
- Carlo Campiciano appointed to fill vacancy; he is a qualified accountant and former CFO of MedAdvisor.
- Director agreement provides $45,000 annual cash compensation paid quarterly.
- Equity compensation of 0.5% to 4.99% based on milestone achievements.
- Campiciano is independent per Nasdaq/NYSE American standards.

## SEC filing metadata
- accession: 0001493152-26-033173
- form_type: 8-K
- ticker: PPCB
- cik: 0001517681
- company_name: Propanc Biopharma, Inc.
- filed_at: 2026-07-14T20:01:28+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517681/000149315226033173/0001493152-26-033173-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517681/000149315226033173/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-033173
- JSON: https://secwatch.observer/filing/0001493152-26-033173.json
- Plain text: https://secwatch.observer/filing/0001493152-26-033173.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.